ReviewVirologica Sinica2016
Virus like particle-based vaccines against emerging infectious disease viruses.
Review in Virologica Sinica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications.MedComm · 2025Review
- Translatability scoring in prospective and retrospective COVID drug development cases.European journal of clinical pharmacology · 2023Article
- Preventative and therapeutic potential of animal milk components against COVID-19: A comprehensive review.Food science & nutrition · 2023Article
- Article
- Zika virus-like particles (VLPs) produced in insect cells.Frontiers in pharmacology · 2023Article
- Applications of Surface Plasmon Resonance and Biolayer Interferometry for Virus-Ligand Binding.Viruses · 2022Review
- Progress on Applying Carbon Dots for Inhibition of RNA Virus Infection.Nanotheranostics · 2022Review
- Article
- An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India.The veterinary quarterly · 2020Review
- Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2.BMC veterinary research · 2020Article
- Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.International journal of antimicrobial agents · 2020Article
- Protective Malaria Vaccine in Mice Based on theVaccines · 2020Article
- Article
- Article
- Bioinspired and Biomimetic Nanotherapies for the Treatment of Infectious Diseases.Frontiers in pharmacology · 2019Review
- Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages.NPJ vaccines · 2019Article
- Zika Virus Baculovirus-Expressed Virus-Like Particles Induce Neutralizing Antibodies in Mice.Virologica Sinica · 2018Article
- Review
- Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.Journal of virology · 2017Article
- Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo.Biomaterials · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging infectious diseases are major threats to human health. Most severe viral disease outbreaks occur in developing regions where health conditions are poor. With increased international travel and business, the possibility of eventually transmitting infectious viruses between different countries is increasing. The most effective approach in preventing viral diseases is vaccination. However, vaccines are not currently available for numerous viral diseases. Virus-like particles (VLPs) are engineered vaccine candidates that have been studied for decades. VLPs are constructed by viral protein expression in various expression systems that promote the selfassembly of proteins into structures resembling virus particles. VLPs have antigenicity similar to that of the native virus, but are non-infectious as they lack key viral genetic material. VLP vaccines have attracted considerable research interest because they offer several advantages over traditional vaccines. Studies have shown that VLP vaccines can stimulate both humoral and cellular immune responses, which may offer effective antiviral protection. Here we review recent developments with VLP-based vaccines for several highly virulent emerging or re-emerging infectious diseases. The infectious agents discussed include RNA viruses from different virus families, such as the Arenaviridae, Bunyaviridae, Caliciviridae, Coronaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, and Togaviridae families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.